Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
(2015) In Journal of Neurology 262(10). p.2201-2213- Abstract
- Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group... (More)
- Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8198654
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Dystonia, Torticollis, Botulinum toxins, Botulinum toxin type A, Decision making, Consensus development conference
- in
- Journal of Neurology
- volume
- 262
- issue
- 10
- pages
- 2201 - 2213
- publisher
- Springer
- external identifiers
-
- wos:000363035800001
- scopus:84944511294
- pmid:25877834
- ISSN
- 1432-1459
- DOI
- 10.1007/s00415-015-7703-x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neurology, Malmö (013027010)
- id
- 7b36d67b-0e81-4792-b425-ed611e28a2c2 (old id 8198654)
- date added to LUP
- 2016-04-01 12:55:34
- date last changed
- 2022-03-21 07:38:16
@article{7b36d67b-0e81-4792-b425-ed611e28a2c2,
abstract = {{Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information.}},
author = {{Albanese, Alberto and Abbruzzese, Giovanni and Dressler, Dirk and Duzynski, Wojciech and Khatkova, Svetlana and Jose Marti, Maria and Mir, Pablo and Montecucco, Cesare and Moro, Elena and Pinter, Michaela and Relja, Maja and Roze, Emmanuel and Skogseid, Inger Marie and Timerbaeva, Sofiya and Tzoulis, Charalampos}},
issn = {{1432-1459}},
keywords = {{Dystonia; Torticollis; Botulinum toxins; Botulinum toxin type A; Decision making; Consensus development conference}},
language = {{eng}},
number = {{10}},
pages = {{2201--2213}},
publisher = {{Springer}},
series = {{Journal of Neurology}},
title = {{Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement}},
url = {{http://dx.doi.org/10.1007/s00415-015-7703-x}},
doi = {{10.1007/s00415-015-7703-x}},
volume = {{262}},
year = {{2015}},
}